natgillin/translations-raw huggingface dataset:
The transdermal delivery device of claim 1, wherein the drug containing layer is a matrix layer, and the matrix preferably comprises a material selected from the group consisting of polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethylacrylate copolymers, ethylenevinyl acetate copolymers, silicones, rubber, rubber-like synthetic homo-, co- or block polymers, polyacrylic esters and the copolymers thereof, polyurethanes, polyisobutylene, chlorinated polyethylene, polyvinylchloride, vinyl chloride-vinyl acetate copolymer, polymethacrylate polymer (hydrogel), polyvinylidene chloride, poly(ethylene terephthalate), ethylene-vinyl alcohol copolymer, ethylene-vinyloxyethanol copolymer, silicones (e.g., silicone copolymers such as polysiloxane-polymethacrylate copolymers), cellulose polymers (e.g., ethyl cellulose, and cellulose esters), polycarbonates, polytetrafluoroethylene and mixtures thereof. 
Sredstvo za transdermalno davanje prema zahtjevu 1, naznačeno time da je sloj koji sadrži lijek matrični sloj, i da matrica poželjno sadrži materijal odabran iz skupine koja se sastoji od polietilena, polipropilena, etilen/propilen kopolimera, etilen/etilakrilat kopolimera, etilenvinil acetatnih kopolimera, silikona, gume, sintetičkih homo-, ko- ili blok polimera sličnih gumi, poliakrilinih estera i njihovih kopolimera, poliuretana, poliizobutilena, kloriranih polietilena, polivinilklorida, vinil klorid-vinil acetat kopolimera, polimera polimetakrilata (hidrogel), poliviniliden klorida, poli(etilen tereftalata), etilen-vinil alkohol kopolimera, etilen-viniloksietanol kopolimera, silikona (npr. silikon kopolimera kao što su polisiloksan-polimetakrilat kopolimera), celuloznih polimera (npr. etil celuloze i estera celuloze), polikarbonata, politetrafluorocetilena i njihovih smjesa. .
The boundaries of the CDR regions (1-3) are shown in Table 3 and Table 4. 
Yablica 1 regija (1-3) u VL i Vi su podvučeni.
A pharmaceutical composition comprising the compound of any one of claims 1 to 7 and a pharmaceutically acceptable diluent or carrier. 
H Farmaceutski spoj koji sadrži spoj iz bilo kojeg od zahtjeva od 1 do 7 i farmaceutski prihvatljiv razrjeđivač ili nosač.
600 Number of nozzles 
Broj međunarodne objave:
represents a piperidinyl group unsubstituted or substituted with one to four fluoro atoms or a CF3 group, or 
R; predstavlja jednu piperidinil skupinu koja nije supstituirana ili je supstituirana jednim do četiri atoma fluora ili jednom skupinom CF, ili
A method as claimed in anyone of the preceding claims, further comprising the step of installing connectors (19) facing outwards and electrically connected to said conductive tracks (16) on said structural element (2, 3, 4, 5, 27, 30). 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se dodatno sastoji u koraku ugradnje konektora (19) okrenutih prema van 1 električno spojenih s navedenim vodljivim trakama (16) na navedenom strukturnom elementu (2, 3, 4, 5, 27,30).
is selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl. 
R' je odabran od vodika, alkila, cikloalkila, arila, heteroarila, i heterociklila.
The method of claim 2, wherein R1 is a divalent residue selected from the group consisting of benzene, divinylbenzene, pyridine, biphenyl and ethylene. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time, da je R; odabran od dvovalentnih ostataka benzena, divinilbenzena, piridina, bifenila ili etilena.
The compound according to claim 1, having the following structure: or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što ima sljedeću strukturu: kN a Doo
the amino acid sequence of residues 25-418 of SEQ ID NO: 12 with a E to S mutation at residue 25; or (iv) the amino acid sequence of residues 25-418 of SEQ ID NO: 12 with a E to S mutation at residue 25 and a C to S mutation at residue 256. 
aminokiselinsku sekvencu ostataka 25-418 od SEQ ID NO: 12 s mutacijom od E do S na ostatku 25 i s mutacijom od C do S na ostatku 256.
An in vitro method for identifying a compound that inhibits bone resorption, comprising: 
identificiranje spoja koji inducira ili pojačava djelovanje ili izražaj osteoprotegerina (OPG).
A compound of formula I according to claim 1 wherein Y represents one of the following groups 
Spoj formule I prema zahtjevu 1, naznačen time, da je spoj odabran iz skupine koja sadrži:
An embodiment of the method for manufacturing a composition suitable for leather tanning comprising zeolite treated with concentrated monocarboxylic acid, among others, includes, (i) providing zeolite having a Si to Al ratio of about 0.7 to 2.5 into a reactor, and (ii) keeping said zeolite in motion while introducing concentrated monocarboxylic acid selected from the group of consisting of: formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, and a mixture thereof, wherein the concentration of said monocarboxylic acid being more than about 84% by weight, thereto provided that the mean temperature of the resulting composition is maintained at a temperature of about 50° C. or below. 
HR P20131068 T1 PATENTNI ZAHTJEVI Postupak za proizvodnju pripravka prikladnog za štavljenje kože koji sadrži zeolit obrađen koncentriranom monokarboksilnom kiselinom, naznačeno time što postupak obuhvaća stavljanje zeolita, u kojem je omjer Si prema Al od 0,7 do 2,5, u reaktor i održavanje tog zeolita u pokretu dok se uvodi koncentrirana monokarboksilna kiselina izabrana iz grupe koju čine mravlja kiselina, octena kiselina, propionska kiselina, glikolna kiselina, mliječna kiselina i njihove smjese, čija je koncentracija veća od 84% težinski, k tome uz uvjet da se prosječna temperatura dobivenog pripravka održava na temperaturi od 50%C ili nižoj.
A method of treating a human subject suffering from Hepatitis B Virus (HBV) infection to reduce the progression of HBV to hepatocellular carcinoma, comprising administering to said subject an effective amount of the double-stranded short interfering nucleic acid (siNA) molecule of claim 1, thereby treating the human subject suffering from Hepatitis B Virus (HBV) infection to reduce the progression of HBV to hepatocellular carcinoma. 
Molekula s dvolančanom kratkom interferirajućom nukleinskom kiselinom (siNA) u skladu s patentnim zahtjevom 1, naznačena time, da se koristi za liječenje ljudi koji pate od infekcije virusom hepatitisa B (HBV) da bi se smanjila učestalost razvoja HBV infekcije u hepatocelularni karcinom.
A precipitate forms which is filtered, washed with water and dried in vacuo to yield the titled product. 
Nastali talog se odfiltrira, ispere s vodom i osuši u vakuumu, čime se dobije naslovni proizvod.
On the way from the first position to the second position and vice versa, an intermediate position is passed, but the user has no knowledge of this. 
Na putu od prvog položaja u drugi položaj 1 obrnuto prolazi se kroz međupoložaj, ali korisnik to ne zna.
The clip assembly according to claim 2, wherein the cheeks of the bracket are secured to the tube by a weld. 
Å tipaljka prema zahtjevu 2, naznačena time, što je pričvršćivanje bočnih strana (4*) obujmice (4) pojačano varom.
Particularly preferred formulations containing xylitol, or xylitol in combination with meglumine are characterized by having an HIC analysis at T4 or T2 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than about 1%; the amount of the composition represented by peak 2 of the HIC chromatogram is greater than about 95 wt. % and preferably greater than about 99 wt. %; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than about 1 wt. %. 
Kompozicija stabilizirana magnezij kloridom prema patentnom zahtjevu 5 koja dovodi do stabilnosti pri dugotrajnom skladištenju, naznačena: HIC analizom u M; ili T> ili Ta gdje je količina kompozicije predstavljena pikom 2 HIC kromatograma veća od, ili jednaka 95 tež.%; 1 gdje je, ukoliko je pik 3 prisutan na HIC kromatogramu, količina kompozicije predstavljena pikom 3 manja od, ili jednaka 3 tež.%.
The compound of claim 30, or a pharmaceutically acceptable salt thereof, wherein the optionally substituted aryl is an optionally substituted phenyl. 
A je H (vodik); ili pri čemu R1A je NH2, po izboru supstituiran mono-supstituirani amin ili po izboru supstituiran dvostruko supstituiran amin.
D is chosen from the series consisting of N(R2), O and S; 
D se bira iz skupine koju čine N(R");
Thus, the current invention provides a host cell comprising a nucleic acid or an expression vector according to the invention. 
Stanica domaćin, sastoji se od nukleinske kiseline ili ekspresijskog vektora u skladu s patentnim zahtjevom 4, pri čemu je navedena stanica po mogućnosti stanica koja eksprimira antigen, naročito dendritična stanica.
the bifunctional crosslinking agent is: (X = -H or -NO2), or respectively and wherein the -C(Y)-N(H)- motif in the conjugates results from the reacting of the imine reactive reagent with the imine-containing cytotoxic compound. 
bifunkcionalni umrežavajući agens je: pri čemu je -C(Y)-N(H)- motiv u konjugatima rezultat reagiranja imin reaktivnog reagensa s citotoksičnim spojem koji sadrži imin.
These results demonstrate that loading CCM at pH 6.1 results in increased capacity and increased concentration of the eluted IL-18BP. 
Ovi rezultati pokazuju da nanošenje CCM-a pri pH 6.2 rezultira povećanim kapacitetom i koncentracijom eluiranog IL- I8BP.
identifying the peptide of which cytotoxic T cell inducibility is same to or higher than a peptide consisting of the original amino acid sequence. 
(v) identificiranja peptida čija je CTL inducibilnost ista kao ili veća nego za peptid koji se sastoji od izvornog aminokiselinskog slijeda,
Method and system for using renewable energy sources 
METODA I SUSTAV ZA UPORABU OBNOVLJIVIH IZVORA ENERGIJE
less than about 4 weight % of the total reaction mixture, and has an average molecular weight of about 50,000 to about 1,000,000 Daltons; and 
(a) manje od 4%, težinski, od ukupne reakcijske smjese, te ima prosječnu molekulsku težinu od 50.000 do 1.000.000 Da; i
the second fragment is a toxin B repeating domain fragment; 
(li) drugi fragment je fragment ponavljane domene toksina B i sadrži najmanje 100 aminokiselina;
is selected from the group consisting of and wherein b is an integer from 0 to 2; and wherein c is 0; 
[image] je izabran iz skupine koja se sastoji od [image] i [image] gdje je b cijeli broj od 0 do 2; i gdje je c 0;
This type of oligofructose contains less free sucrose and/or fructose and has a fixed distribution of polymerisation. 
Ta vrsta oligofruktoze sadržava manje slobodne saharoze iili fruktoze i ima fiksnu raspodjelu polimerizacije.
A composition according to claim 10 optionally, further comprising an antipsychotic agent. 
Pripravak prem azahtjevu 24, koji se nadalje sastoji od antipsihotičkog agensa.
Thus, the sheath device may in this case be rotationally connected directly to the endoscopic instrument. 
Daklc, u tom slučaju može uređaj za omatanje biti dircktno spojen na endoskopski instrument, tako da može rotirati.
The mouse of any one of the preceding claims, wherein the endogenous λ (lambda) light chain allele comprises at least 12, at least 28, or at least 40 unrearranged human Vλ gene segments. 
Miš prema bilo kojem od prethodnih zahtjeva, naznačen time, što se alel endogenog lakog A (lambda) lambda sastoji od: (a) najmanje 12 nepreuređenih humanih segmenata gena V2; ili
A method according to claim 5 and claim 2, wherein some of the compressed gases derived from the hydrates are conveyed to the seabed (3) to assist in transporting the slurry to the surface. 
Metoda u skladu s patentnim zahtjevom 5 1 patentnim zahtjevom 2, pri čemu su neki od stlačenih plinova dobivenih iz hidrata preneseni na morsko dno (3) za pomoć u transportu mulja na površinu.
a device configured to gasify the LNG installed downstream of the high-pressure pump, to gasify the compressed LNG; and a fuel gas supply line connected from the LNG tank to the high-pressure gas injection engine of the vessel, wherein the boil-off gas reliquefaction apparatus includes a heat exchanger installed along the fuel gas supply line between the LNG tank and the high-pressure gas injection engine, and wherein the boil-off gas from an upper portion of the LNG tank is in thermal communication with the LNG while passing through the heat exchanger and then is supplied to the fuel gas supply line. 
uređaj konfiguriran da uplinjava LNG koji je postavljen nizvodno od druge crpke, za uplinjavanje dodatno komprimiranog LNG; te vod za dobavu pogonskog plina (L1) spojen od spremnika LNG na visokotlačni plinski injekcijski motor plovila, uređaj za ukapljivanje isparenog plina koji radi tako da ukapljuje ispareni plin koji nastaje u spremniku LNG uključujući izmjenjivač topline (3) postavljen uzduž voda za dobavu pogonskog plina između spremnika LNG i visokotlačnog plinskog injekcijskog motor, te naznačen time da je ispareni plin iz gornjeg dijela spremnika LNG (1) u toplinskoj komunikaciji s komprimiranim LNG dok prolazi kroz izmjenjivač topline i zatim se dovodi u vod za dobavu pogonskog plina.
The process of paragraph 14, wherein said inorganic base is selected from the group consisting of LiOH, KOH, NaOH, Ca(OH)2, Li2CO3, Na2CO3, K2CO3, and Cs2CO3. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedenu anorgansku bazu se bira iz skupine koju čine LiOH, KOH, NaOH, Ca(OH),, L2C0,, NaC0g, K2CO; 1 Cs&COs.
The fusion protein according to any one of the claims 1 to 3, which between domain (a) and domain (b) or between domains (b) contains domain (c) containing protease cleavage site, selected from a sequence recognized by metalloprotease MMP, a sequence recognized by urokinase uPA, and sequence recognized by furin and a sequence recognized by native furin. 
Fuzijski protein prema bilo kojem od zahtjeva 1 do 3, naznačen time da između domene (a) i domene (b) ili između domena (b) sadrži domenu (c) koja sadrži mjesto cijepanja proteaze, odabrano iz sekvence koju prepoznaje metaloproteaza MMP, sekvence koju prepoznaje urokinaza uPA, i sekvence koju prepoznaje furin i sekvence koju prepoznaje izvorni furin.
compressing the combined first waste stream, sorbent, and second waste stream to form a densified engineered fuel feedstock. The method of claim 1, wherein: the temperature of the combined first waste stream and sorbent is increased to at least 350 °C; 
Postupak sukladno patentnom zahtjevu 1, naznačeno time da: a) = temperatura kombiniranog prvo toka otpada je povećana na najmanje 350 "C; b) prvi tok otpada obuhvaća u osnovi tvrdu plastiku i meku plastiku;
The preferred amount of the monohydric alcohol is about 25% to about 85% and most preferably from about 35% to about 75%. 
Poželjna količina monohidratnog alkohola je oko 25 % do oko 85 % i najpoželjnije od oko 35 % do oko 75 %.
23, a L-CDR2 sequence which is 29% or more identical to the L-CDR2 sequence shown in SEQ ID NO. 
23, (v) slijed L-CDR2, koji je 29% ili više istovjetan slijedu L-CDR2 prikazanom u SEQ ID NO.
A is selected from the group consisting of phenyl, pyridyl, indolyl, thienyl, benzothienyl, indazolyl, benzisoxazolyl, benzofuranyl, benzotriazolyl, furanyl, benzothiazolyl, thiazolyl, each optionally substituted with one or two groups independently selected from the group consisting of OH, lower alkyl, lower cycloalkyl; 
A je izabran iz grupe koju čine fenil, piridil, pirazolil, indolil, tienil, benzotienil, indazolil, benzizoksazolil, benzofuranil, benzotriazolil, furanil, benzotiazolil, tiazolil, svaki izborno supstituiran sa jednom ili dvije grupe nezavisno izabrane iz grupe koju čine OH, C,4 alkil,
wherein the heterologous amino acid sequence encodes an immunogen, a T-cell epitope, a B-cell epitope, a fragment of any of said heterologous peptides, and a combination of two or more of said heterologous peptides. 
(b) pri čemu heterologna sekvenca aminokiseline kodira imunogen, epitop T-stanica, epitop B-stanica, odsječak bilo kojeg od navedenih heterolognih peptida, i kombinaciju dva ili više navedenih heterolognih peptida.
In yet another aspect of the present invention said organic material may be selected from the group consisting of sludge, such as sewage sludge, liquid manure, corn silage, clarifier sludge, black liquor, residues from fermentation, residues from juice production, residues from edible oil production, residues from fruit and vegetable processing, residues from food and drink production, leachate or seepage water or a combination thereof. 
Metoda u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu je navedeni organski materijal odabran iz grupe koja se sastoji od taloga, kao što je sanitarni talog, tekuće gnojivo, kukuruzna silaža, talog od bistrenja, crni liker, ostaci od fermentacije, ostaci od proizvodnje soka, ostaci od proizvodnje jestivog ulja, ostaci od obrade voća 1 povrća, ostaci od proizvodnje hrane 1 pića, eluat ili cijeđena voda ili njihova kombinacija.
cooling and dehumidifying said air stream as a result of heat transfer between the cooled water and the air stream. The method according to claim 12 or 13, further including the steps of: introducing the second water circulation system (10) into an air stream of an air handling unit, and; 
Postupak u skladu s patentnim zahtjevom 12 ili 13, naznačen time što dodatno uključuje korake: uvođenja drugog sustava za kruženje vode (10) u struju zraka u jedinici za obradu zraka, i; dodatnog hlađenja navedene struja zraka zbog prijenosa topline između ohlađene vode 1 struje zraka.
The method of aspect 1, wherein the antibody or fragment thereof is selected from the group consisting of a recombinant antibody, an antibody having reduced effector function, a chimeric, and a humanized or human antibody. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time što se monoklonsko protutijelo protiv MASP-3 ili njegov fragment bira iz skupine koju čini rekombinantno protutijelo, protutijelo sa smanjenom efektorskom funkcijom, kimerno, te humanizirano ili ljudsko protutijelo.
a second conveying means for conveying at least a portion of the solid products of the biomass pyrolysis back to the heat transfer medium input port, so that the heat transfer medium includes said solid products of the biomass pyrolysis. 
Postupak pirolize biomase prema zahtjevu 1 ili 2, naznačen time, da medij za prijenos topline uključuje krute toplinske kuglice koje prenose toplinsku energiju.
Arthritis Rheum 2005;52:3371-80 . A glucocorticoid contained in a delayed-release dosage form for use in the treatment of a patient suffering from signs and symptoms of an underlying rheumatic disease and/or ostheoarthritis, wherein said treatment is administered once daily for at least two weeks. 
Glukokortikoid sadržan u obliku doziranja s odgođenim otpuštanjem za uporabu u liječenju bolesnika koji pate od znakova i simptoma bolesti koja ima reumatsku podlugu i/ili osteoartritisa, pri čemu se navedeno liječenje provodi davanjem lijeka jednom dnevno kroz najmanje dva tjedna.
and R6′, together with the N-atom to which they are attached, form a (C5-C10)heterocyclyl group. 
Rs i Rs', zajedno s N-atomom na kojeg su vezani, tvore (Cs-C,o)heterociklilnu skupinu.
The high-modulus glass fiber composition of claim 1 comprising the following components expressed as weight percentage: SiO2 
Pripravak od fiberglasa visokih svojstava sukladno zahtjevu 1, pri čemu obuhvaća sljedeće komponente izražene kroz težinski postotak:
A compound as claimed in any of claims 1-4 for use in the treatment of psychosis or a psychotic condition, or for treatment of substance abuse. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1-20, naznačen time što je namijenjen upotrebi liječenju psihoze ili psihotičnog stanja, ili liječenju zloupotrebe tvari.
with at least one sensing position (12) provided along a longitudinal extent of the keyway (11), 
-sbaremjednim mjestom za raspoznavanje (12), koje se nalazi uzdužno na ključanici (11) Cc.
Demattei et al, Journal of Organic Chemistry, Vol 66, No 10, 2001, pages 3330-3337 discloses a possible anticancer agent, ABT-271 possessing a 9a,10B hydroxyl groups. 
J. Demattci i drugi, Journal of Organic Chemistry, vol. 66, br. 10, 2001, strane 3330-3337, otkriva mogući lijck protiv karcinoma, ABT-271 koji ima 9%, 10B hidroksilne skupine.
a pick-up frame for picking up, tilting and replacing the container; and 
okvir za podizanje (4) za podizanje, naginjanje i ponovno postavljanje spremnika; i
The optical element (OP) according to claim 5 or 6, wherein the exit surface of the optical element has a tilted upper portion which in use is to shade a relatively lower portion of the exit surface from snow and/or dust. 
Optički element (OP) u skladu sa patentnim zahtjevom 5 ili 6, pri čemu izlazna površina optičkog elementa ima nagnuti gornji dio koji tijekom primjene štiti relativno niži dio izlazne površine od snijega i/ili prašine.
or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer, or a deuterated analog thereof, wherein: 
(IVa-2) ili njegova farmaceutski prihvatljiva sol, solvat, tautomer, stereoizomer, ili deuterirani analog, naznačen time da:
Use of an MMVF substrate according to any of claims 16 to 19, or an MMVF substrate formed from MMVF that has been made by a method according to any of claims 1 to 9, as (a) technical insulation or (b) for fire protection in an industrial or marine environment. 
Uporaba MMVF supstrata sukladno bilo kojem od zahtjeva 16 do 19, ili MMVF supstrat oblikovan od MMVE dobivenog postupkom sukladno bilo kojem od zahtjeva 1 do 9, kao (a) tehnička izolacija ili (b) za zaštitu od požara u industrijskom ili morskom okolišu.
The mixture was poured into water and extracted with ethyl acetate; the combined organic phases were washed with water and brine, dried over sodium sulfate and concentrated under reduced pressure. 
Smjesu se izlije u vodu, te ekstrahira etil-acetatom; pomiješane organske faze ispere se vodom i slanom vodom, osuši preko natrijevog sulfata, te koncentrira pod sniženim tlakom.
A recombinant RhCMV or HCMV vector comprising a nucleic acid sequence encoding a heterologous antigen, wherein the heterologous antigen is a human pathogen-specific antigen or a tumor antigen, wherein the vector is replication-deficient and comprises a deletion in the RhCMV Rh110 or HCMV UL82 gene encoding pp71. 
Rekombinantni RhCMV ili HCMV vektor koji sadrži sekvencu nukleinske kiseline koja kodira heterologni antigen, pri čemu heterologni antigen je ljudski patogen specifičan antigen izoliran iz virusa ljudske imunodeficijencije (HIV), naznačen time da vektor uključuje brisanje jednog ili više gena RhCMV ili HCMV gena koji su esencijalni za ili povećavaju replikaciju.
The memory device of claim 1, wherein data stored in the memory device comprises information regarding an associated replaceable printer component. 
Zamjenjiva komponenta pisača (108) u skladu s patentnim zahtjevom 1, naznačena time što svaka oznaka (TO- T15) definira tip i duljinu podataka spremljenih u dijelu.
A pharmaceutical composition comprising the acid addition salt according to claim 1 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak koji sadrži kombinaciju sukladno bilo kojem od patentnih zahtjeva 1 do 7 i farmaceutski prihvatljiv nosač.
A wound dressing as claimed in claim 1 wherein the pore or mesh size of the open structure is between 3.0 mm2 to 4.0 mm2. 
Zavoj za rane prema zahtjevu 1 naznačen time da je veličina pora ili mreže otvorene strukture između 3.0 mm" do 4.0 mm.
"alkyl" as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of a hydrocarbon compound having from 1 to 20 carbon atoms (unless otherwise specified), which may be aliphatic or alicyclic, and which may be saturated or unsaturated (e.g. 
"alkil" kako se ovdje koristi, odnosi se na jednovalentnu skupinu dobivenu uklanjanjem vodikovog atoma iz ugljikovog atoma iz spoja ugljikovodika koji ima od 1 do 20 ugljikovih atoma (osim ako nije drugačije naznačeno), HR P20120963 T1 koji može biti alifatski ili aliciklički, te koji može biti zasićen ili nezasićen (npr.